Stockscreener 앱 받기
54.80
0.65%
-0.3382
전일 마감가:
$55.14
열려 있는:
$55.37
하루 거래량:
436.68K
Relative Volume:
0.19
시가총액:
$9.13B
수익:
$1.56B
순이익/손실:
$152.72M
주가수익비율:
60.93
EPS:
0.8994
순현금흐름:
$221.80M
1주 성능:
+4.55%
1개월 성능:
+27.99%
6개월 성능:
+86.58%
1년 성능:
+87.41%
1일 변동 폭
$53.63
$55.67
1주일 범위
$50.96
$55.67
52주 변동 폭
$25.16
$55.67
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
54.80 | 9.10B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
16.99 | 52.99B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.85 | 43.25B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.77 | 40.34B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.43 | 31.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
557.65 | 23.60B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-11-11 | 개시 | Truist | Buy |
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Insider Sell: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
Alkermes stock hits 52-week high at 55.28 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 55.28 USD - Investing.com
Alkermes (ALKS) EVP David Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) notice: David Gaffin lists proposed Common Stock sales in 2026 - Stock Titan
Price to earnings forward of Alkermes plc – NASDAQ:ALKS - TradingView
Granules India secures sole First-to-File status for generic drug - The Times of India
ALKSAlkermes plc Volatility & Greeks - Finviz
(ALKS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion - simplywall.st
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
ALKS Maintains Rating by Mizuho -- Price Target Raised to $65 - GuruFocus
Mizuho raises Alkermes stock price target to $65 on narcolepsy drug potential - Investing.com
Alkermes (ALKS) R&D chief exercises 5,000 options and sells 9,000 shares - Stock Titan
Alkermes (ALKS) shows multiple 9,000-share insider sales, exercise and vesting - Stock Titan
Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 AdditionWhat's Changed - Yahoo Finance
A Look at Alkermes PLC (ALKS) After 4.8% Decline -- GF Value $31 - GuruFocus
Alkermes plummets on mid-stage Alixorexton data for narcolepsy - MSN
ALKS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
ALKS Downgraded by B of A Securities -- Rating Changed to Underp - GuruFocus
BofA downgrades Alkermes stock rating on valuation concerns By Investing.com - Investing.com Australia
BofA downgrades Alkermes stock rating on valuation concerns - Investing.com
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Enterprise value to EBIT forward of Alkermes plc – NASDAQ:ALKS - TradingView
Press Release: Alkermes to Report First Quarter Financial Results on May 5, 2026 - Moomoo
Price to sales forward of Alkermes plc – NASDAQ:ALKS - TradingView
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda - BioPharma Dive
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI
Alkermes Public Limited Company Actuals & Estimates (NASDAQ:ALKS) - TradingView
ALKS Forecast — Price Target — Prediction for 2027 - TradingView
Alkermes stock hits 52-week high at 51.77 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 51.77 USD - Investing.com
Liquidity Mapping Around (ALKS) Price Events - Stock Traders Daily
Alkermes Jumps 6.9% After Needham Maintains Buy - AlphaStreet
ALKS Maintained by Needham -- Price Target Raised to $61.00 - GuruFocus
Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tel - GuruFocus
ALKS Maintained by TD Cowen -- Price Target Raised to $50 - GuruFocus
Alkermes plc (ALKS) Stock Analysis: Navigating Growth in Biopharmaceuticals with a 4.88% Upside - DirectorsTalk Interviews
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alkermes presents detailed positive results from Vibrance-2 phase 2 study of Alixorexton in adults with narcolepsy type 2 at SLEEP 2026 - MSN
Alkermes announces orphan drug designations for Alixorexton in the US and Europe - MSN
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS) - Seeking Alpha
Did Positive Vibrance-2 Data for Alixorexton Just Shift Alkermes' (ALKS) Investment Narrative? - simplywall.st
Alkermes stock hits 52-week high at 45.76 USD By Investing.com - Investing.com India
Alkermes stock hits 52-week high at 45.76 USD - Investing.com
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Alkermes (ALKS): Piper Sandler Lowers Price Target, Maintains Ov - GuruFocus
Alkermes (ALKS) Study Results Highlight Potential Benefits for N - GuruFocus
Needham raises Alkermes stock price target on narcolepsy drug data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Alkermes stock rating on trial data By Investing.com - Investing.com South Africa
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.92%
2.11%
자본화:
|
볼륨(24시간):